Catalyst

Slingshot members are tracking this event:

Boehringer Ingelheim Announces Phase 3 Results for Humira Biosimilar Candidate in Active Rheumatoid Arthritis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
Boehringer Ingelheim

100%
ABBV

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 26, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Active Rheumatoid Arthritis, Humira, Biosimilar, Phase 3, Results